MAPK7 and neoplasm: By using a newly developed BMK1 inhibitor (XMD8-92), the authors were able to demonstrate efficient anti-tumor effect in vitro and in multiple xenotransplants in vivo, which was achieved by specific restoration of PML and downstream activation of p21.